Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma

Cheng,Zhongping; Yang,Weihong; Guo,Jing; Luo,Ning; Chen,Li; Xie,Yan; Qu,Xiaoyan; Hu,Liping; Dai,Hong; Zuo,Xiaoming

doi:10.3892/ol.2016.4933

Genetic landscape of a case of extraovarian peritoneal serous papillary carcinoma

Authors:
- Zhongping Cheng
- Weihong Yang
- Jing Guo
- Ning Luo
- Li Chen
- Yan Xie
- Xiaoyan Qu
- Liping Hu
- Hong Dai
- Xiaoming Zuo
View Affiliations

Affiliations: Department of Gynecology and Obstetrics, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China, Department of Pathology, Yangpu Hospital, School of Medicine, Tongji University, Shanghai 200090, P.R. China
Published online on: August 2, 2016 https://doi.org/10.3892/ol.2016.4933
Pages: 2395-2402
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present report aimed to study genetic alterations underlying extraovarian peritoneal serous papillary carcinoma (EPSPC), which have not previously been systematically investigated. A case of EPSPC was identified, and its genetic alterations were assessed by combining comparative genomic hybridization and whole-exome sequencing technologies to investigate the genomic landscape, including copy number variations and mutations in EPSPC. It was found that a large number of germline mutations were present, which may have predisposed the patient to the occurrence of this disease. Copy number gains were found in a range of chromosomes, including 4q, 5q, 8q, 10q, 15q, 16p, 18q, 20p, 20q and Xq. Large-scale copy number loss occurred in chromosomes 2p, 13q, 16q, 17p and 17q. Through use of whole‑exome sequencing, germline mutations were widely found that were associated with cancer development, including mutations in the BRCA1, DNA repair associated (BRCA1), BRCA2, tumor protein 53, erb‑b2 receptor tyrosine kinase 2, matrix metalloproteinases and ADAM metallopeptidase domain-containing genes. In addition, 165 somatic mutations, including 52 missense mutations and 7 short insertions or deletions, were also identified. In summary, the EPSPC was undergoing profound genomic rearrangement and somatic mutation, which may have led to its initiation and development, and the present study discussed the genetic basis of this highly malignant cancer.

View Figures

View References

1	Swerdlow M: Mesothelioma of the pelvic peritoneum resembling papillary cystadenocarcinoma of the ovary; case report. Am J Obstet Gynecol. 77:197–200. 1959. View Article : Google Scholar : PubMed/NCBI
2	Bloss JD, Liao SY, Buller RE, Manetta A, Berman ML, McMeekin S, Bloss LP and DiSaia PJ: Extraovarian peritoneal serous papillary carcinoma: A case-control retrospective comparison to papillary adenocarcinoma of the ovary. Gynecol Oncol. 50:347–351. 1993. View Article : Google Scholar : PubMed/NCBI
3	Bhuyan P, Mahapatra S, Sethy S, Parida P and Satpathy S: Extraovarian primary peritoneal papillary serous carcinoma. Arch Gynecol Obstet. 281:561–564. 2010. View Article : Google Scholar : PubMed/NCBI
4	Pentheroudakis G and Pavlidis N: Serous papillary peritoneal carcinoma: Unknown primary tumour, ovarian cancer counterpart or a distinct entity? A systematic review. Crit Rev Oncol Hematol. 75:27–42. 2010. View Article : Google Scholar : PubMed/NCBI
5	Goodman MT and Shvetsov YB: Rapidly increasing incidence of papillary serous carcinoma of the peritoneum in the United States: Fact or artifact? Int J Cancer. 124:2231–2235. 2009. View Article : Google Scholar : PubMed/NCBI
6	Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 9:1191–1197. 2008. View Article : Google Scholar : PubMed/NCBI
7	Grant DJ, Moorman PG, Akushevich L, Palmieri RT, Bentley RC and Schildkraut JM: Primary peritoneal and ovarian cancers: An epidemiological comparative analysis. Cancer Causes Control. 21:991–998. 2010. View Article : Google Scholar : PubMed/NCBI
8	Gao YN, Liu JX, Wang W, Li WF and Tang WS: Comparison of primary extraovarian peritoneal serous papillary carcinoma with stage III–IV ovarian papillary serous carcinoma. Zhonghua Zhong Liu Za Zhi. 27:171–173. 2005.(In Chinese). PubMed/NCBI
9	Kowalski LD, Kanbour AI, Price FV, Finkelstein SD, Christopherson WA, Seski JC, Naus GJ, Burnham JA, KanbourShakir A and Edwards RP: A case-matched molecular comparison of extraovarian versus primary ovarian adenocarcinoma. Cancer. 79:1587–1594. 1997. View Article : Google Scholar : PubMed/NCBI
10	Cass I, Baldwin RL, Fasylova E, Fields AL, Klinger HP, Runowicz CD and Karlan BY: Allelotype of papillary serous peritoneal carcinomas. Gynecol Oncol. 82:69–76. 2001. View Article : Google Scholar : PubMed/NCBI
11	Huang LW, Garrett AP, Schorge JO, Muto MG, Bell DA, Welch WR, Berkowitz RS and Mok SC: Distinct allelic loss patterns in papillary serous carcinoma of the peritoneum. Am J Clin Pathol. 114:93–99. 2000. View Article : Google Scholar : PubMed/NCBI
12	Bandera CA, Muto MG, Schorge JO, Berkowitz RS, Rubin SC and Mok SC: BRCA1 gene mutations in women with papillary serous carcinoma of the peritoneum. Obstet Gynecol. 92:596–600. 1998. View Article : Google Scholar : PubMed/NCBI
13	Schorge JO, Muto MG, Welch WR, Bandera CA, Rubin SC, Bell DA, Berkowitz RS and Mok SC: Molecular evidence for multifocal papillary serous carcinoma of the peritoneum in patients with germline BRCA1 mutations. J Natl Cancer Inst. 90:841–845. 1998. View Article : Google Scholar : PubMed/NCBI
14	McBride DJ, Etemadmoghadam D, Cooke SL, Alsop K, George J, Butler A, Cho J, Galappaththige D, Greenman C, Howarth KD, et al: Tandem duplication of chromosomal segments is common in ovarian and breast cancer genomes. J Pathol. 227:446–455. 2012. View Article : Google Scholar : PubMed/NCBI
15	Castellarin M, Milne K, Zeng T, Tse K, Mayo M, Zhao Y, Webb JR, Watson PH, Nelson BH and Holt RA: Clonal evolution of high-grade serous ovarian carcinoma from primary to recurrent disease. J Pathol. 229:515–524. 2013. View Article : Google Scholar : PubMed/NCBI
16	Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, Rosner J, Shumansky K, Kalloger S, Senz J, et al: Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol. 231:21–34. 2013. View Article : Google Scholar : PubMed/NCBI
17	Winklmeier A, ContrerasShannon V, Arndt S, Melle C and Bosserhoff AK: Cadherin-7 interacts with melanoma inhibitory activity protein and negatively modulates melanoma cell migration. Cancer Sci. 100:261–268. 2009. View Article : Google Scholar : PubMed/NCBI
18	Tanaka M, Sasaki K, Kamata R, Hoshino Y, Yanagihara K and Sakai R: A novel RNA-binding protein, Ossa/C9orf10, regulates activity of Src kinases to protect cells from oxidative stress-induced apoptosis. Mol Cell Biol. 29:402–413. 2009. View Article : Google Scholar : PubMed/NCBI
19	Leung YK, Mak P, Hassan S and Ho SM: Estrogen receptor (ER)-beta isoforms: A key to understanding ER-beta signaling. Proc Natl Acad Sci USA. 103:13162–13167. 2006. View Article : Google Scholar : PubMed/NCBI